Your new post is loading...
At Solvanix we have developed StAbilize™ to improve the stability of human antibodies. The StAbilize™ process optimizes amino acids at specific locations within the antibody complementarity determining regions (CDRs). The result is a fully human antibody with significantly increased stability and a reduced propensity to aggregate that still retains all the properties necessary for therapeutic use.
StAbilize™ can be used for all antibodies in development to improve characteristics and reduce the future manufacturing and commercial risk. StAbilize™ can also improve antibodies that would otherwise fail to meet manufacturability requirements. The technology is directly applicable to a wide range of antibody formats, including fragments, bi-specifics and full-length IgG monoclonals.
StAbilize™ can be rapidly implemented and tested using highly predictive methods, and can be applied to phage display libraries.
The technology has been validated by improving the stability of a broad range of currently marketed therapeutic antibodies as well as drug candidates while maintaining binding and other critical functions.
Via Krishan Maggon
Advantages of StAbilize™ technology:
efficient and cost effective manufacturing,high concentration drug delivery,increased shelf-life,reduced formulation complexity,improved cold-chain logistics, andpotential to reduce immunogenicity risk.So now our antibodies are unstable...and of course are in need of an expensive dose of suppliments